Introduction
Macular Diseases
Subliminal laser therapy: a macular treatment

There remains an unmet need in the treatment of macular diseases. Increasing evidence demonstrates SubLiminal laser therapy to be safe and effective for macular conditions such as DME and CSC.

A macular treatment

Treatment guidelines

Testimonials

Clinical data
Peripheral Retinal Diseases
Subliminal laser therapy: not a peripheral treatment

Several studies demonstrate that retinal destruction was required to control the neovascularization process in PDR. For peripheral conditions Multispot laser photocoagulation should be favored.

Multispot for PRP treatment

Treatment guidelines

Testimonials

Clinical data
Media Library

Archives: PDF

The Argument for Laser in 2021

30/09/2021

When discussing treatment for macular pathologies like diabetic macular edema (DME) and central serous chorioretinopathy (CSCR), injection burden is a term that often appears.

Formation of the Subthreshold Ophthalmic Laser Society

30/09/2021

Laser photocoagulation has been used in ophthalmology for many years. During photocoagulation, a continuous wave of energy is delivered to the target tissue throughout the entire duration of the laser pulse.

SubLiminal Laser Therapy for CSC

25/08/2021

Central serous chorioretinopathy (CSC) is a common posterior pole disease with a high recurrence rate and etiology. Its pathogenesis is ambiguous; however, it is characterized by the decompensation of the retinal pigment epithelium (RPE) and usually results in serous detachment of neuroretina, serous pigment epithelium detachment (PED), and RPE atrophy.

Retina Treatment: Subliminal Treatment Procedure

25/02/2021

Retina Treatment: Subliminal Treatment Procedure by Victor CHONG, MD (UK), Royal Free London NHS Foundation Trust, Optegra Eye Hospital, Central London

Multispot Treatment Guidelines

13/02/2021

Easyret Treatment Guidelines: Multispot mode

SubLiminal Laser for Center-Involving Diabetic Macular Edema

20/12/2020

Diabetic retinopathy (DR) is a major microvascular complication of diabetes. It is estimated that by 2030, nearly 200 million people will be affected by this disease. During this period, visionthreatening DR will increase from 37 million to 56 million people globally. Center-involved diabetic macular edema (CI-DME) is the most common cause of decreased visual acuity in DR patients, affecting more than 750,000 patients in the United States alone.

Safe and Effective Laser Therapies: Targeting Retinal Diseases Amidst COVID-19

28/09/2020

In this time of uncertainty, one thing is certain (at least in ophthalmology): Retinal pathologies are not going anywhere. In fact, chronic conditions like age-related macular degeneration (AMD) and diabetic retinopathy (DR) are thought to be causing more concerns during this period of worldwide lockdown and social distancing.

An Exciting Journey in SubLiminal Laser Treatment Therapy for DME

20/07/2020

DME is one of the most common causes of sightthreatening retinopathy for people with diabetes, which currently affects more than 30 million people worldwide. As the prevalence of diabetes and vision diseases related to diabetes continues to rise, so does the burden it creates on health care systems.

Subthreshold yellow laser for fovea-involving diabetic macular edema in a series of patients with good vision

20/07/2020

Patients with center-involved diabetic macular edema (CI-DME) with good visual acuity (VA) represent a controversial clinical scenario in which a subthreshold laser might be a reasonable approach. We report a case series of patients with CI-DME with VA better than 20/32 who were treated with a subthreshold 577 nm (yellow) laser.

Macular laser photocoagulation in the management of diabetic macular edema: Still relevant in 2020?

20/05/2020

Macular laser photocoagulation (MLP) is inferior to intravitreal vascular endothelial growth factor (VEGF) inhibitors in the treatment of center-involved diabetic macular edema (DME). Ultra-widefield fluorescein angiography-guided laser photocoagulation to presumed ischemic areas of the peripheral retina or MLP do not reduce the treatment burden nor improve the visual outcomes of eyes treated with anti-VEGF drugs.

Since 1993, Quantel Medical develops, manufactures and markets innovative medical laser and ultrasound solutions.
World leader in ophthalmology, its lasers and ultrasounds are designed to diagnose and treat the four main causes of blindness: cataracts, glaucoma, diabetic retinopathy and macular degeneration; and also dry eye disease.

More info

Name
First Last
Country*
Country
Email*
Consent*
I agree that Quantel Medical uses my personal data for the purpose of sending me the requested information services via email newsletter. I confirm that I have read and accept the privacy policy.
Data policy

Site plan – Terms & Conditions – Privacy policy – Cookie policy